Drug Search Results
More Filters [+]

Hydromorphone

Alternative Names: hydromorphone, dilaudid, hydromorphonhydrochlorid, palladone, exalgo
Latest Update: 2024-07-12
Latest Update Note: News Article

Product Description

Hydromorphone is used to relieve pain. Hydromorphone extended-release tablets are used to relieve severe pain in people who are expected to need pain medication around the clock for a long time and who cannot be treated with other medications.

Mechanisms of Action: OPRD Agonist,OPRK Agonist,OPRM Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Egypt | Estonia | Finland | France | Germany | Hungary | Iceland | Indonesia | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | New Zealand | Norway | Portugal | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States

Approved Indications: Pain Unspecified | Pain Unspecified | Morphine Dependence | Substance Abuse Unspecified

Known Adverse Events: Dizziness | Pruritus | Flushing | Headache | Constipation

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Hydromorphone

Countries in Clinic: China, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Acute Pain|Morphine Dependence|Pain, Postoperative

Phase 1: Oncology Unspecified|Pain Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

STUDY19030022

P3

Recruiting

Pain, Postoperative|Acute Pain|Morphine Dependence

2024-12-30

CTR20212615

P1

Not yet recruiting

Pain Unspecified|Oncology Unspecified

None

Recent News Events